KUKJEON PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,490 KRW | -0.36% |
|
+0.37% | -12.02% |
| Sales 2022 | 104B 75.4M 6.28B | Sales 2023 | 122B 88.69M 7.39B | Capitalization | 306B 223M 18.55B |
|---|---|---|---|---|---|
| Net income 2022 | 8.95B 6.51M 542M | Net income 2023 | 4.82B 3.51M 292M | EV / Sales 2022 | 2.79 x |
| Net cash position 2022 | 35.63B 25.9M 2.16B | Net Debt 2023 | 13.95B 10.14M 845M | EV / Sales 2023 | 2.62 x |
| P/E ratio 2022 |
583
x | P/E ratio 2023 |
63.7
x | Employees | 160 |
| Yield 2022 * |
-
| Yield 2023 |
0.16% | Free-Float | 38.01% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.36% | ||
| 1 week | +0.37% | ||
| Current month | -10.15% | ||
| 1 month | -13.95% | ||
| 3 months | -7.42% | ||
| 6 months | -4.19% | ||
| Current year | -12.02% |
1 week
5 450.00
5 650.00
1 month
5 420.006 370.00
Current year
5 420.007 090.00
1 year
5 420.008 140.00
3 years
4 230.0024 900.00
5 years
4 230.0024 900.00
10 years
4 230.0024 900.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Ho Hong
CEO | Chief Executive Officer | 53 | - |
Dong-Woon Kim
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Jong-Hak Lee
BRD | Director/Board Member | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seon-Gyu Choi
BRD | Director/Board Member | 70 | - |
Jong-Ho Hong
CEO | Chief Executive Officer | 53 | - |
Jong-Hak Lee
BRD | Director/Board Member | 53 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 5,490 | -0.36% | 104,549 |
| 25/24/25 | 5,510 | -1.08% | 70,084 |
| 24/24/24 | 5,570 | +0.36% | 55,524 |
| 23/24/23 | 5,550 | 0.00% | 85,554 |
| 22/24/22 | 5,550 | +1.46% | 88,349 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
Kukjeon Pharmaceutical Co Ltd, formerly Daishin Balance No.6 Special Purpose Acquisition Co Ltd, is a Korea-based company mainly engaged in the manufacture and sale of drug substances. The Company manufactures and sells raw materials used in specialized medicines such as choline alfoscerates, benfothiamines, spherical sorbents, and napamostat mesylatse. The Company sells its products in domestic and overseas markets such as Japan.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.02% | 196M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- A307750 Stock
